137 related articles for article (PubMed ID: 38178286)
1. Repurposing and discovery of transmembrane serine protease 2 (TMPRSS2) inhibitors as prophylactic therapies for new coronavirus disease 2019 (COVID-19).
Yang H; Lin X; Yu Q; Awadasseid A; Zhang W
Pharmazie; 2023 Dec; 78(11):217-224. PubMed ID: 38178286
[TBL] [Abstract][Full Text] [Related]
2. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
3. Structure-based drug repositioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages.
Singh N; Decroly E; Khatib AM; Villoutreix BO
Eur J Pharm Sci; 2020 Oct; 153():105495. PubMed ID: 32730844
[TBL] [Abstract][Full Text] [Related]
4. Structural analysis of experimental drugs binding to the SARS-CoV-2 target TMPRSS2.
Huggins DJ
J Mol Graph Model; 2020 Nov; 100():107710. PubMed ID: 32829149
[TBL] [Abstract][Full Text] [Related]
5. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
6. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.
Kosinsky Y; Peskov K; Stanski DR; Wetmore D; Vinetz J
Microbiol Spectr; 2022 Apr; 10(2):e0216721. PubMed ID: 35412356
[TBL] [Abstract][Full Text] [Related]
7. Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model.
Choi Y; Shin B; Kang K; Park S; Beck BR
Viruses; 2020 Nov; 12(11):. PubMed ID: 33218024
[TBL] [Abstract][Full Text] [Related]
8. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.
Kumar V; Dhanjal JK; Bhargava P; Kaul A; Wang J; Zhang H; Kaul SC; Wadhwa R; Sundar D
J Biomol Struct Dyn; 2022 Jan; 40(1):1-13. PubMed ID: 32469279
[TBL] [Abstract][Full Text] [Related]
9. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety.
Breining P; Frølund AL; Højen JF; Gunst JD; Staerke NB; Saedder E; Cases-Thomas M; Little P; Nielsen LP; Søgaard OS; Kjolby M
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):204-212. PubMed ID: 33176395
[TBL] [Abstract][Full Text] [Related]
10. Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges.
Mahmoud IS; Jarrar YB
Mol Biol Rep; 2021 May; 48(5):4667-4675. PubMed ID: 34023987
[TBL] [Abstract][Full Text] [Related]
11. The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19.
Mantzourani C; Vasilakaki S; Gerogianni VE; Kokotos G
Expert Opin Drug Discov; 2022 Mar; 17(3):231-246. PubMed ID: 35072549
[TBL] [Abstract][Full Text] [Related]
12. The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment.
Wettstein L; Kirchhoff F; Münch J
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163273
[TBL] [Abstract][Full Text] [Related]
13. Impact of SARS-CoV-2 Spike Mutations on Its Activation by TMPRSS2 and the Alternative TMPRSS13 Protease.
Stevaert A; Van Berwaer R; Mestdagh C; Vandeput J; Vanstreels E; Raeymaekers V; Laporte M; Naesens L
mBio; 2022 Aug; 13(4):e0137622. PubMed ID: 35913162
[TBL] [Abstract][Full Text] [Related]
14. The Transmembrane Protease Serine 2 (TMPRSS2) Non-Protease Domains Regulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike-Mediated Virus Entry.
Strobelt R; Adler J; Shaul Y
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896901
[TBL] [Abstract][Full Text] [Related]
15. In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2).
Barge S; Jade D; Gosavi G; Talukdar NC; Borah J
Eur J Pharm Sci; 2021 Jul; 162():105820. PubMed ID: 33775827
[TBL] [Abstract][Full Text] [Related]
16. Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19.
Shrimp JH; Janiszewski J; Chen CZ; Xu M; Wilson KM; Kales SC; Sanderson PE; Shinn P; Schneider R; Itkin Z; Guo H; Shen M; Klumpp-Thomas C; Michael SG; Zheng W; Simeonov A; Hall MD
ACS Infect Dis; 2022 Jun; 8(6):1191-1203. PubMed ID: 35648838
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Eur J Pharmacol; 2021 Apr; 896():173922. PubMed ID: 33539819
[TBL] [Abstract][Full Text] [Related]
18. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
19. Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion.
Kaur U; Chakrabarti SS; Ojha B; Pathak BK; Singh A; Saso L; Chakrabarti S
Curr Drug Targets; 2021; 22(2):192-201. PubMed ID: 32972339
[TBL] [Abstract][Full Text] [Related]
20. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
Ramakrishnan J; Kandasamy S; Iruthayaraj A; Magudeeswaran S; Chinnasamy K; Poomani K
Appl Biochem Biotechnol; 2021 Jun; 193(6):1909-1923. PubMed ID: 33512650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
